| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/2159-8290.CD-16-0297 |
| P698 | PubMed publication ID | 27325282 |
| P50 | author | Federica Perrone | Q42617207 |
| Ludovic Barault | Q46213944 | ||
| Federica Morano | Q50206087 | ||
| Adele Busico | Q56850318 | ||
| Giulia Siravegna | Q56862949 | ||
| Alessandra Alessi | Q58376583 | ||
| Daniele Oddo | Q87685393 | ||
| Federica Di Nicolantonio | Q28321686 | ||
| Alberto Bardelli | Q28321691 | ||
| Filippo de Braud | Q37837953 | ||
| Filippo Pietrantonio | Q37838216 | ||
| Maria Di Bartolomeo | Q37838236 | ||
| Annunziata Gloghini | Q38322915 | ||
| P2093 | author name string | Emanuele Valtorta | |
| Marta Caporale | |||
| Rosa Berenato | |||
| Ambra Vittoria Gualeni | |||
| P2860 | cites work | MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 |
| Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. | Q34307548 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| P304 | page(s) | 963-971 | |
| P577 | publication date | 2016-06-20 | |
| P1433 | published in | Cancer Discovery | Q15724440 |
| P1476 | title | MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer | |
| P478 | volume | 6 |
| Q38650454 | Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. |
| Q97525750 | Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance |
| Q28468571 | Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors |
| Q47767987 | BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives |
| Q91754859 | Biomarker-guided therapy for colorectal cancer: strength in complexity |
| Q60912537 | CD44v6 engages in colorectal cancer progression |
| Q27612411 | CIViC database |
| Q33569864 | Cancer Transcriptome Dataset Analysis: Comparing Methods of Pathway and Gene Regulatory Network-Based Cluster Identification |
| Q92257010 | Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment |
| Q50066241 | Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer |
| Q50047679 | Convergent therapeutic strategies to overcome the heterogeneity of acquired resistance in BRAFV600E colorectal cancer |
| Q90702159 | Current advances of targeting HGF/c-Met pathway in gastric cancer |
| Q46636066 | Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer |
| Q38706872 | Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer |
| Q47113667 | Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation |
| Q89498248 | Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers |
| Q41548672 | Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient |
| Q52318134 | Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. |
| Q91789111 | MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis |
| Q96230891 | MET-dependent solid tumours - molecular diagnosis and targeted therapy |
| Q37597850 | MET/HGF pathway activation as a paradigm of resistance to targeted therapies. |
| Q47739142 | Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. |
| Q91361655 | Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours |
| Q39164873 | Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance. |
| Q37710556 | Molecular Testing for Gastrointestinal Cancer. |
| Q98386286 | Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer |
| Q88727587 | Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities |
| Q60960810 | Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases |
| Q50092066 | Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer |
| Q55113736 | Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. |
| Q92578812 | Resistance to TRK inhibition mediated by convergent MAPK pathway activation |
| Q57050008 | Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation |
| Q89948388 | SOX13 promotes colorectal cancer metastasis by transactivating SNAI2 and c-MET |
| Q64087532 | Sequencing and curation strategies for identifying candidate glioblastoma treatments |
| Q38856729 | Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges |
| Q38730744 | The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer |
| Q95642655 | Tissue gene mutation profiles in patients with colorectal cancer and their clinical implications |
| Q64240932 | Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient |
| Q55689035 | Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. |
| Q64961076 | miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling. |
Search more.